Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAM2029 versus octreotide LAR or lanreotide in GEP-NET
2023-508723-12-00Phase 3Authorised
- Sponsor
- Camurus
- Start
- Dec 2023
- Modality
- Peptides
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of octreotide in Gastroenteropancreatic Carcinoid Tumor (2 arms), sponsored by Camurus. Primary endpoint: Progression-free survival (BIRC-assessed). Planned start Dec 2023; status: authorised.
02
Drugs
octreotide
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on 2023-508723-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508723-12-00.